Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia
Open Access
- 17 November 2009
- journal article
- case report
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2009, 1-2
- https://doi.org/10.1155/2009/867380
Abstract
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, characterized by the presence of a peripheral blood absolute plasma cell count of at least/l and more than 20% circulating plasma cells. The prognosis of PCL patients remains poor. Even by using autologous or allogenic transplant procedures, median survival does not exceed 3 years (Saccaro et al., 2005). Thalidomide, bortezomib and lenalidomide (Revlimid) have emerged as high active agents in the treatment of PCL (Johnston and abdalla, 2002; Musto et al., 2007; Finnegan et al., 2006). In particular, Lenalidomide is a structural analogue of thalidomide with similar but more potent biological activity; it is used as first line therapy in MM (Palumbo et al., 2007; Niesvizky et al., 2007), although information regarding its associated use with dexamethasone use as salvage therapy in PCL derives from anecdotal single case reports (Musto et al., 2008). We would like to describe a case of primary PCL with adverse cytogenetic in which excellent response was achieved with the combination of lenalidomide, melphalan, and prednisone as salvage therapy.
Keywords
This publication has 8 references indexed in Scilit:
- Advances in therapy of multiple myelomaCurrent Opinion in Oncology, 2008
- Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemiaLeukemia Research, 2008
- Multiple myelomaBlood, 2008
- Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trialBlood, 2008
- Efficacy and safety of bortezomib in patients with plasma cell leukemiaCancer, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Bortezomib is effective in primary plasma cell leukemiaLeukemia & Lymphoma, 2006
- Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem‐cell transplantation and review of the literatureAmerican Journal of Hematology, 2005